Ad Scientiam Launches Programs to Develop Digital Biomarkers for Chronic Neurological Diseases
PARIS, FRANCE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- On Rare Disease Day, Ad Scientiam, a leader in digital biomarkers, announced the launch of two ambitious programs to develop and validate novel digital biomarkers for the self-assessment of patients suffering from generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorders (NMOSD). The programs will leverage assets, methodologies and expertise built by Ad Scientiam over the past five years and are supported by Alexion, AstraZeneca Rare Disease.
gMG and NMOSD are chronic severe diseases in which progression is complex and critical to monitor. The course of NMOSD is driven by episodes of severe, sequential relapses leading to the accrual of permanent disability, while gMG is characterized by a heterogeneous collection of symptoms (including fatigue and muscle group weakness) which fluctuate over time.
Currently, no objective measurement tools exist to allow gMG and NMOSD patients to track their symptoms over time. Digital biomarkers are patient-generated physiological and behavioral measures that are collected from digital devices like smartphones and processed by algorithms. If clinically validated, these measures could provide data to improve the remote monitoring of disease symptoms.
"We believe that empowering patients through real-time digital data sharing could strengthen communication between patients and healthcare professionals, and may enable more informed disease management decisions," said Dr. Guido Sabatella, Global Medical Lead in Neurology at Alexion.
"Easy-to-use digital tools have the potential to generate reliable and objective data to better understand the real impact of the disease on patients' lives and also have the potential to demonstrate the benefits of novel therapies to keep disease under control," explains Matthieu Lamy, Ad Scientiam's President.
Scoping phases have been conducted for both programs to identify clinically meaningful digital biomarkers to monitor patients living with NMOSD or gMG. Ongoing research will inform the development of a digital medical device intended to be used by patients as a self-assessment tool.
"International, multicenter, comparative studies against clinical gold standards, such as the Quantitative Myasthenia Gravis score and assessments of visual function, ambulation and dexterity in NMOSD, will be deployed to confirm the clinical relevance of selected digital biomarkers," according to Dr. Saad Zinaï, Ad Scientiam's Chief Medical Officer.
About Ad Scientiam
We strongly believe that continuously monitoring the progression of severe and disabling diseases in real life is crucial for delivering better care.
To achieve this, we create and clinically validate digital biomarkers that make visible these previously undetectable changes. These biomarkers are developed using data collected through smartphones and transformed using proprietary algorithms.
Hospital institutions such as the Paris Brain Institute (ICM) and pharmaceutical companies, including Biogen, Janssen, Roche, Pfizer, Vertex, and Novartis, trust us. In 2019, we launched MSCopilot®, the first CE-marked software medical device for the self-assessment of patients with multiple sclerosis. We are currently validating new devices in neuroscience, rare diseases, and mental disorders. Ad Scientiam is ISO 13485 certified.
Check our LinkedIn and Facebook page, or visit adscientiam.com.
Press contact: info@adscientiam.com
Contact Information:
Saad Zinaï
Chief Medical Officer
szinai@adscientiam.com
+33768008666
Matthieu Lamy
President
mlamy@adscientiam.com
+33768008666
Related Files
FEB2023_Ad Scientiam digital biomarkers PR_Final_for Newswire.pdf
Related Images
To view this piece of content from cdn.newswire.com, please give your consent at the top of this page.
Image 1: Ad Scientiam Logo
This content was issued through the press release distribution service at Newswire.com.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS23.3.2023 01:31:57 CET | Press release
SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). On the question, “Is the available evidence sufficient to conclude that a reduction in plasma neurofilament light chain (NfL) concentration in tofersen-treated patients is reasonably likely to predict clinical benefit of tofersen for treatment of patients with SOD1-ALS?” the Committee voted unanimously yes (9 yes to 0 no), for consideration of a potential accelerated approval. On the second question, “Does the clinical data from the placebo-controlled study and available long-term extension study results, with additional supporting res
GN Store Nord announces change to the Board of Directors22.3.2023 22:22:29 CET | Press release
Due to sudden serious health issues in the family, Montserrat Maresch Pascual has decided to step down from the Board of Directors of GN Store Nord A/S. The Chairmanship assesses that the remaining five members of the Board possess all the relevant competencies and experience to govern the company. Consequently, GN’s Board of Directors as of today consists of Jukka Pekka Pertola (Chair), Klaus Holse (Deputy chair), Anette Weber, Hélène Barnekow, Ronica Wang, and members elected by the employees: Leo Larsen, Cathrin Inge Hansen, and Claus Holmbeck-Madsen. For further information, please contact: Investor Relations Anne Sofie Staunsbæk Veyhe +45 45 75 85 06 Rune Sandager +45 45 75 92 57 Media Relations Steen Frentz Laursen +45 20 65 34 20 About GN GN facilitates communication between people through intelligent hearing, audio, video, and gaming technology. Inspired by people and driven by our passion for innovation, we leverage technologies to deliver unique user experiences that bring pe
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 202222.3.2023 22:05:00 CET | Press release
ERYTECH Provides Business and Financial Update for the Fourth Quarterand Full Year 2022 Combination with Pherecydesannounced, intending to create a global leader in extended phage therapies targeting antimicrobial resistant pathogenic bacteria Deep restructuring implemented; team size reduced by approximately 75% since start of 2022Cash and cash equivalents of €38.8million ($41.5 million) at the end of December 2022 Cambridge, MA (U.S.) and Lyon (France),March 22, 2023– ERYTECH Pharma (Nasdaq & Euronext: ERYP),aclinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided a business and financial updatefor thefourth quarterand full year of2022. “After the disappointing results of our Phase 3 trial in pancreatic cancer, we have pursued during 2022 a consistent strategy to maximize the remaining value for our shareholders through strategic partnering. We sold our US manufacturing site, sharply
Hvidbjerg Banks ordinære generalforsamling den 22. marts 202322.3.2023 21:48:49 CET | pressemeddelelse
Formand Henrik H. Galsgaard udpegede advokat Rasmus Kronborg, Thisted til dirigent i henhold til vedtægternes § 9. Rasmus Kronborg takkede for valget og konstaterede, at generalforsamlingen var korrekt indvarslet og beslutningsdygtig med hensyn til generalforsamlingens dagsorden, som blev gennemgået. Dagsordenens punkt 1: Formand Henrik H. Galsgaard aflagde på bestyrelsens vegne mundtlig beretning om bankens virksomhed i det forløbne år. På grund af kommende kapitalkrav forventes der ikke udbetalt udbytte i de kommende år. Der var ikke kommet bemærkninger eller spørgsmål, hvorefter dirigenten konstaterede, at beretningen var taget til efterretning. Dagsordenens punkt 2 og 3: Bankdirektør Jens Odgaard fremlagde årsrapporten til godkendelse og årsrapporten blev godkendt. Årets resultat t.kr. 25.172 blev vedtaget overført således: Udbytte 0 Rente hybrid kernekapital 975 Henlagt til egenkapitalen 24.197 I alt anvendt 25.172 Dagsordenens punkt 4: Bestyrelsesformand Henrik H. Galsgaard freml
CNH Industrial: Periodic Report on $300 Million Buyback Program. Completion of Second $50 million tranche and launch of Third $50 million tranche22.3.2023 21:30:00 CET | Press release
London, March 22, 2023 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) announces that it has completed the second tranche of its $50 million share buyback (the “Second Tranche”) in the framework of its $300 million common share buyback program with the transaction described in the table below. The transaction, completed on March 13, 2023, reported in aggregate, was based on automatic orders placed with the Company’s broker (who made its trading decisions as to the timing of the purchases independently of the Company based on instructions given before the commencement of the Company’s closed period under the applicable regulations). After the purchases announced today and considering those previously executed under the Second Tranche, the total invested amount is approximately €46,863,453.43 ($49,999,997.50) for a total amount of 3,065,368 common shares purchased. DateNumber of common shares purchasedAverage price per share excluding feesConsideration excluding fees Consideration (**) exclu